Gabriela Szpila

Gabriela Szpila

Auto-generated profile, based on publicly available information

Gabriela Szpila

Military Clinical Hospital with Polyclinic in Wrocław, Wrocław, Poland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
GSGabriela Szpila
Gabriela Szpila
JSJulia Szczotka
Julia Szczotka
ASAlexander Suchodolski
Alexander Suchodolski
MSMariola Szulik
Mariola Szulik
Endometriosis, traditionally viewed as a gynecological disorder, is increasingly recognized as a systemic disease with significant cardiovascular implications. Recent studies suggest that women with endometriosis are at higher risk for developing atherosclerosis and other cardiovascular diseases (CVDs), due to chronic systemic inflammation, endothelial dysfunction, oxidative stress, and metabolic disturbances. This review aimed to summarize current evidence on the vascular implications of endometriosis. A literature search was conducted in PubMed and Google Scholar, focusing on studies exploring the relationship between endometriosis and cardiovascular risk. In rare cases, endometriosis can affect extrapelvic locations such as the diaphragm or pericardium, presenting with cyclical chest pain or dyspnea and mimicking cardiopulmonary conditions. These atypical manifestations often delay diagnosis and highlight the need for heightened clinical awareness. Advances in imaging and minimally invasive techniques, including robotic surgery, have improved the detection and management of such presentations. Shared molecular pathways between endometriosis and CVDs, including pro-inflammatory cytokines and metabolic dysregulation, provide a rationale for exploring novel therapeutic approaches. Emerging pharmacologic options such as statins, metformin, or antiplatelet agents may offer dual benefits for both reproductive and cardiovascular health. Given the multifactorial nature of endometriosis, a multidisciplinary approach involving gynecologists, cardiologists, and primary care providers is essential. These findings highlight the need for early cardiovascular risk assessment and tailored preventive strategies in this population.

27 July 2025 in E-methodology
Verified
Journal Article
Open access
PDF file
KSKarolina Szałata
Karolina Szałata
MCMonika Czekalska
Monika Czekalska
LŁLuiza Łabuzińska
Luiza Łabuzińska
MBMartyna Bukowiec
Martyna Bukowiec
WWWeronika Worosz
Weronika Worosz
AĆAngela Ćwil
Angela Ćwil
Aim. Online surveys have become a vital tool in health research due to their cost- effectiveness, speed, and global reach. However, their methodological limitations – par- ticularly various forms of bias – may affect the validity and generalisability of findings. This review aims to provide an overview of the most common types of bias in online health surveys and to discuss strategies for their mitigation. Methods. A narrative literature review was conducted to identify and categorise the primary sources of bias associated with online survey research in health-related contexts. The review focused on three main areas: survey design and presentation bias, cognitive and psychological response biases, and selection bias. Studies addressing these issues were examined to extract examples and recommended mitigation approaches. Results. The review identified several key sources of bias. Poor survey design, exces- sive length, or misleading visual formatting – was associated with reduced data quality and increased dropout rates. Response biases, such as social desirability, recall errors, or avoidance of sensitive questions, were found to skew data, particularly in self- reported health measures. Selection bias emerged as a major concern, as access to and familiarity with digital technologies significantly influences who participates in online surveys. Indi- viduals with poorer health or limited digital literacy are often underrepresented. Conclusions. Despite their numerous advantages, online health surveys are vulner- able to various forms of bias that can compromise data validity. Researchers must care- fully consider survey design, sample recruitment, and respondent characteristics. Apply- ing strategies such as pre-testing, use of clear language, adaptive sampling techniques, and bias correction methods can enhance the quality of online survey data. When ethical standards are upheld and methodological rigour is applied, online surveys can remain a powerful and reliable tool in public health research.

16 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
JGJoanna Gadzinowska
Joanna Gadzinowska
ATAleksandra Tomaszewska
Aleksandra Tomaszewska
ALAngelika Lewandowska
Angelika Lewandowska
GSGabriela Szpila
Gabriela Szpila
AAAgata Paulina Andrzejczyk
Agata Paulina Andrzejczyk
NNNatalia Nafalska
Natalia Nafalska
Schizophrenia is a severe and chronic mental disorder that affects up to 1% of the general population. Research suggests that the most effective therapeutic approach combines medication with non-pharmacological strategies. This review explores the impact of non-pharmacological treatment on the course of schizophrenia, including its effects on key symptoms, as well as patients' quality of life and overall life satisfaction. This article is a comprehensive review based on articles obtained from scientific databases such as PubMed and Google Scholar, with sources selected based on their relevance and significance to the subject matter. The findings indicate that non-pharmacological treatments, including lifestyle modifications, psychosocial interventions, and neuromodulation training play a crucial role in improving the quality of life for individuals with schizophrenia. There is evidence supporting the reduction of both negative and positive symptoms, as well as an increased likelihood of returning to everyday activities. Non-pharmacological strategies are integral to the comprehensive management of schizophrenia. While the effectiveness of pharmacological interventions is well-established, current clinical guidelines also highlight the complementary role of non-pharmacological treatments, which contribute meaningfully to therapeutic outcomes and overall patient well-being.

19 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MSMałgorzata Stopyra
Małgorzata Stopyra
KFKrzysztof Feret
Krzysztof Feret
AAAgata Paulina Andrzejczyk
Agata Paulina Andrzejczyk
NNNatalia Nafalska
Natalia Nafalska
ATAleksandra Tomaszewska
Aleksandra Tomaszewska
ALAngelika Lewandowska
Angelika Lewandowska
Introduction: Autoimmune diseases are a heterogeneous group of disorders characterized by dysregulated immune responses against self-antigens, leading to chronic inflammation and progressive organ damage. Despite advances in immunosuppressive and biologic therapies improving outcomes in conditions like systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis (MS), a subset of patients exhibit suboptimal responses or experience significant adverse effects. Additionally, access to certain biologic treatments may be limited by strict eligibility criteria. Metabolic comorbidities such as obesity, insulin resistance, and type 2 diabetes are prevalent in patients with autoimmune diseases and can exacerbate inflammation, accelerate organ damage, and diminish therapeutic efficacy. Glucagon-like peptide-1 receptor agonists (GLP-1RA), a class of drugs originally developed for type 2 diabetes and obesity, have demonstrated pleiotropic effects extending beyond glycemic control, including modulation of immune cell function, suppression of pro-inflammatory cytokine release, and improvement of endothelial function. These immunometabolic properties suggest that GLP-1RA could serve as promising adjunctive agents in managing autoimmune diseases, particularly in patients with coexisting metabolic disturbances. Materials and Methods: The article was written based on scientific papers available on PubMed and Google Scholar Key findings: Evidence gathered indicates that GLP-1 receptor agonists exert significant immunomodulatory and metabolic effects that may translate into clinical benefits across multiple autoimmune diseases. In psoriasis and psoriatic arthritis, where chronic Th1/Th17-driven inflammation often coexists with obesity and insulin resistance, GLP-1RA therapy has been associated with improvements in inflammatory markers and disease severity indices (such as PASI for skin lesions and DAPSA for joint disease), alongside substantial weight reduction and better glycemic control. Multiple sclerosis models and preliminary clinical observations suggest that GLP-1RA can attenuate neuroinflammation and promote neuroprotection: these agents reduce pathogenic Th1/Th17 cell activity, inhibit microglial activation, and may enhance remyelination processes, thereby potentially decreasing relapse rates and neurological damage. In systemic lupus erythematosus, a small retrospective analysis indicated that adjunctive GLP-1RA use led to significant weight loss and improved metabolic profiles without provoking new organ involvement or severe flares; notably, no acceleration of lupus disease activity was seen over short-term follow-up, aligning with GLP-1RA’s known cardiovascular and renal protective effects. (An isolated case of GLP-1RA–induced lupus has been reported, underscoring the need for vigilance.) In rheumatoid arthritis, in vitro studies on fibroblast-like synoviocytes demonstrated that GLP-1RA (e.g., lixisenatide, dulaglutide) can suppress the production of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and matrix-degrading enzymes (MMP-1, -3, -13) by inhibiting NF-κB and MAPK signaling pathways, thereby potentially protecting joint cartilage and bone. Early clinical studies and case series in RA patients (especially those with coexisting type 2 diabetes or obesity) reported reduced disease activity scores (DAS28), lower C-reactive protein and erythrocyte sedimentation rate levels, fewer swollen joints, and diminished morning stiffness during GLP-1RA treatment, along with the expected weight reduction and improved insulin sensitivity. In type 1 diabetes mellitus, which involves autoimmune β-cell destruction, adjunctive therapy with GLP-1RA (such as exenatide, liraglutide, or semaglutide) has shown promise in patients with residual β-cell function. These agents consistently reduced exogenous insulin requirements and facilitated modest improvements in glycemic control (including lower HbA1c and increased time-in-range on continuous glucose monitoring) while promoting weight loss. In honeymoon-phase or early type 1 diabetes mellitus GLP-1RA addition even enabled temporary insulin independence in a few cases. However, across these studies, gastrointestinal side effects were common, and a few instances of euglycemic ketosis were noted, indicating that careful patient selection and monitoring are necessary. Overall, the integration of GLP-1RA into the treatment of autoimmune diseases has yielded partial improvements in disease control and significant benefits in managing metabolic comorbidities, though these benefits are often contingent on disease severity and the presence of a metabolic-inflammatory phenotype. No evidence to date suggests that GLP-1RA can replace standard immunotherapies; rather, they function as complementary agents that address an often overlooked metabolic component of autoimmunity. Conclusions: Autoimmune diseases remain a therapeutic challenge, as many patients achieve only incomplete remission and continue to endure disease-related damage and comorbidities under current treatment paradigms. Glucagon-like peptide-1 receptor agonists offer a novel, multidimensional approach that simultaneously targets metabolic dysregulation and immune aberrations. The current body of evidence indicates that GLP-1RA can confer additional clinical benefits – such as reducing systemic inflammation, improving disease activity metrics, aiding weight loss, and lowering cardiovascular risk – especially in patients whose autoimmune disease is compounded by obesity or insulin resistance. These agents represent a promising adjunct to existing therapies, potentially bridging a gap between metabolic syndrome management and immunomodulation in autoimmune care. However, their therapeutic impact appears to be partial and disease-specific, often providing symptomatic relief or slowing disease activity rather than inducing full...

22 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
GSGabriela Szpila
Gabriela Szpila
ALAngelika Lewandowska
Angelika Lewandowska
NNNatalia Nafalska
Natalia Nafalska
MSMałgorzata Stopyra
Małgorzata Stopyra
KFKrzysztof Feret
Krzysztof Feret
ATAleksandra Tomaszewska
Aleksandra Tomaszewska
Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by disturbances in intestinal motility, alterations in gut microbiota, visceral hypersensitivity, and dysregulation of the gut-brain axis. In recent years, interest has increased in the potential role of physical activity as a supportive, non-pharmacological intervention for symptom management, particularly in individuals who engage in recreational exercise. This review aims to summarize current evidence on the association between physical activity and IBS symptoms, with a focus on physiological mechanisms, stress-related pathways, and the integration of wearable health technologies. Relevant publications, including clinical trials, systematic reviews, and meta-analyses published between 2016 and 2025, were identified through PubMed, Scopus, and Google Scholar. Studies examining gastrointestinal physiology, neuroendocrine responses to exercise, and digital monitoring tools were included. Findings suggest that regular exercise promotes intestinal peristalsis, supports microbial diversity, and reduces low-grade inflammation through immune modulation. Physical activity also contributes to lowering cortisol levels and balancing neurotransmitter activity within the gut–brain axis. Moderate-intensity activities, such as walking or cycling, appear particularly beneficial in alleviating gastrointestinal and psychological symptoms. Furthermore, wearable devices-including fitness trackers, smartwatches, and HRV monitors-offer opportunities to personalize exercise regimens by capturing real-time physiological data and correlating it with symptom fluctuations. In conclusion, moderate and consistent physical activity shows promise as an adjunctive therapeutic approach in IBS management. The incorporation of wearable technologies facilitates individualized treatment strategies and underscores the need for continued interdisciplinary research in this rapidly evolving field.

9 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
JSJulia Szczotka
Julia Szczotka
GSGabriela Szpila
Gabriela Szpila
RFRemigiusz Flakus
Remigiusz Flakus
ŻKŻaneta Kania
Żaneta Kania
GKGabriela Kapłon
Gabriela Kapłon
KGKarolina Glajcar
Karolina Glajcar
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder worldwide and constitutes a significant public health concern due to its rising incidence and the absence of curative therapies. This review synthesizes recent pharmacological progress in the treatment of AD, with particular emphasis on emerging therapeutic strategies and investigational drug classes. The analysis draws on clinical trial data, regulatory documents, and peer-reviewed literature published between 2017 and 2025, identified through major scientific databases including PubMed, Scopus, and ClinicalTrials.gov. The most promising advances are associated with monoclonal antibodies directed against amyloid-beta pathology, such as aducanumab, lecanemab, and donanemab, which show potential to modify disease progression but also raise concerns related to efficacy, safety, and regulatory approval. Additional innovative approaches, including tau-targeted therapies, gene editing technologies such as CRISPR-Cas9, and RNA interference (RNAi), present new therapeutic opportunities, though they remain limited by challenges such as amyloid-related imaging abnormalities (ARIA), restricted delivery across the blood–brain barrier, and uncertainties regarding long-term clinical outcomes. While currently available pharmacological options are insufficient to halt or reverse AD, recent advancements, particularly in antibody-based therapies, represent an important step toward a new therapeutic era. Nevertheless, cautious interpretation of preliminary findings and rigorous clinical validation remain essential before these strategies can be translated into widespread clinical practice.